PHILADELPHIA––In its quest to become the dominant SGLT2 diabetes med for heart failure, Eli Lilly and Boehringer Ingelheim’s Jardiance has used real-world data to beat up on its GLP-1 rivals. But Jardiance isn’t resting there. Now it’s touting DPP-4 inhibitor-topping data to support its case, too.
A three-year interim analysis from the real-world Emprise study showed Jardiance cut the risk of heart failure hospitalizations and matched the risk of non-fatal CV events compared with DPP-4 and GLP-1 inhibitors in Type 2 diabetes patients with or without cardiovascular disease. That analysis was presented Saturday at the American Heart Association Scientific Sessions.
Jardiance notched a 41% relative risk reduction in hospitalizations compared with DPP-4 inhibitors like AstraZeneca’s Onglyza and Merck’s Januvia, and a 17% reduction against GLP-1 receptor agonists like Novo Nordisk’s Victoza and Lilly’s own Trulicity.
For atherosclerotic events, Jardiance showed similar risk rates to both DPP-4s and GLP-1s.
The Emprise study, which began enrollment in 2016 and is expected to read out after five years, is meant to be a real-world “complement and add-on” to Jardiance’s Empa-Reg outcomes study, which showed a 35% risk reduction over placebo in Type 2 diabetes patients with established CVD.
Mohamed Eid, Boehringer’s VP of clinical development and medical affairs for cardio-metabolism and respiratory medicine, said the real-world confirmation––and expansion––of Empa-Reg’s findings offers a better understanding of how drugs work in a broader range of patients.
“Having data in the real-world setting allows healthcare professionals to make more informed decisions about what’s helping patients outside the clinical setting,” Eid said. “It’s important for us to look at the diversity of patients who should be treated.”
RELATED: Lilly, BI’s Jardiance tops GLP-1s at cutting heart failure hospitalization in real-world study
